Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
March 1, 1982
Initial pharmacology and toxicology of intravenous desmethylmisonidazole
C N Coleman, T H Wasserman, T L Phillips, et al.
The British Journal of Radiology
|
February 1, 1980
The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone
T H Wasserman, T L Phillips, G Van Raalte, et al.
Cancer
|
October 20, 1999
Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051)
T H Wasserman, G R Petroni, F E Millard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2000
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
D M Brizel, T H Wasserman, M Henke, et al.
The American Journal of Physiology
|
October 1, 1991
Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole
R S Hotchkiss, R S Rust, C S Dence, et al.
The British Journal of Radiology
|
December 1, 1978
The neurotoxicity of misonidazole: pooling of data from five centres
S Disch, M I Saunders, P Anderson, et al.
The British Journal of Cancer. Supplement
|
June 1, 1978
The hypoxic cell sensitizer programme in the United States
T L Phillips, T H Wasserman, JohnsonRJ, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 1989
Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial
J R Simpson, M Bauer, C A Perez, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 1979
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer
T H Wasserman, T L Phillips, R J Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2001
Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04
J B Owen, P W Grigsby, T M Caldwell, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
International Journal of Radiation Oncology, Biology, Physics
|
March 1, 1982
Initial pharmacology and toxicology of intravenous desmethylmisonidazole
C N Coleman, T H Wasserman, T L Phillips, et al.
The British Journal of Radiology
|
February 1, 1980
The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone
T H Wasserman, T L Phillips, G Van Raalte, et al.
Cancer
|
October 20, 1999
Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051)
T H Wasserman, G R Petroni, F E Millard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2000
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
D M Brizel, T H Wasserman, M Henke, et al.
The American Journal of Physiology
|
October 1, 1991
Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole
R S Hotchkiss, R S Rust, C S Dence, et al.
The British Journal of Radiology
|
December 1, 1978
The neurotoxicity of misonidazole: pooling of data from five centres
S Disch, M I Saunders, P Anderson, et al.
The British Journal of Cancer. Supplement
|
June 1, 1978
The hypoxic cell sensitizer programme in the United States
T L Phillips, T H Wasserman, JohnsonRJ, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 1989
Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial
J R Simpson, M Bauer, C A Perez, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 1979
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer
T H Wasserman, T L Phillips, R J Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2001
Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04
J B Owen, P W Grigsby, T M Caldwell, et al.
Page
of 9